← Browse by Condition
Medical Condition
acute lymphoblastic leukemia
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2, Phase 2
Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.
Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.
Frequently Asked Questions — acute lymphoblastic leukemia Clinical Trials
How many clinical trials are currently recruiting for acute lymphoblastic leukemia?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for acute lymphoblastic leukemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for acute lymphoblastic leukemia?
acute lymphoblastic leukemia research spans Phase 1 (2 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a acute lymphoblastic leukemia clinical trial?
Eligibility criteria for acute lymphoblastic leukemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 6
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05442515 Phase 1, Phase 2
Recruiting
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Enrollment
126 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06533748 Phase 2
Recruiting
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Enrollment
128 pts
Location
United States
Sponsor
St. Jude Children's Research H...
NCT04195633 Phase 2
Recruiting
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Enrollment
60 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT06220487 Phase 2
Recruiting
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Enrollment
67 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
NCT06886074 Phase 2
Recruiting
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Enrollment
30 pts
Location
Mexico
Sponsor
Hospital Universitario Dr. Jos...
NCT06364423 Phase 1, Phase 2
Recruiting
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Enrollment
132 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology